Padma Sampath

Padma Sampath

Auto-generated profile, based on publicly available information

Padma Sampath

Department of Surgery, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, Pennsylvania, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2015 in Nature Medicine
Verified
Journal Article
Closed access
CICarolina Ilkow
Carolina Ilkow
MMMonique Marguerie
Monique Marguerie
CBCory Batenchuk
Cory Batenchuk
JMJustin Mayer
Justin Mayer
DNDaniela Ben Neriah
Daniela Ben Neriah
JBJohn C Bell
John C Bell

14 December 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JRJuan Jose Rojas
Juan Jose Rojas
PSPadma Sampath
Padma Sampath
WHWeizhou Hou
Weizhou Hou
STSteve H. Thorne
Steve H. Thorne
Purpose: Recent data from randomized clinical trials with oncolytic viral therapies and with cancer immunotherapies have finally recapitulated the promise these platforms demonstrated in preclinical models. Perhaps the greatest advance with oncolytic virotherapy has been the appreciation of the importance of activation of the immune response in therapeutic activity. Meanwhile, the understanding that blockade of immune checkpoints (with antibodies that block the binding of PD1 to PDL1 or CTLA4 to B7-2) is critical for an effective antitumor immune response has revitalized the field of immunotherapy. The combination of immune activation using an oncolytic virus and blockade of immune checkpoints is therefore a logical next step. Experimental Design: Here, we explore such combinations and demonstrate their potential to produce enhanced responses in mouse tumor models. Different combinations and regimens were explored in immunocompetent mouse models of renal and colorectal cancer. Bioluminescence imaging and immune assays were used to determine the mechanisms mediating synergistic or antagonistic combinations. Results: Interaction between immune checkpoint inhibitors and oncolytic virotherapy was found to be complex, with correct selection of viral strain, antibody, and timing of the combination being critical for synergistic effects. Indeed, some combinations produced antagonistic effects and loss of therapeutic activity. A period of oncolytic viral replication and directed targeting of the immune response against the tumor were required for the most beneficial effects, with CD8+ and NK, but not CD4+ cells mediating the effects. Conclusions: These considerations will be critical in the design of the inevitable clinical translation of these combination approaches. Clin Cancer Res; 21(24); 5543–51. ©2015 AACR. See related commentary by Slaney and Darcy, p. 5417

1 April 2011 in Molecular Therapy
Verified
Journal Article
Open access
JLJun Li
Jun Li
MOMark O'MAlley
Mark O'MAlley
JUJulie Urban
Julie Urban
PSPadma Sampath
Padma Sampath
Zong Sheng GuoZong Sheng Guo
Zong Sheng Guo
DBDavid L Bartlett
David L Bartlett
Tumor vaccines can induce robust immune responses targeting tumor antigens in the clinic, but antitumor effects have been disappointing. One reason for this is ineffective tumor infiltration of the cytotoxic T lymphocytes (CTLs) produced. Oncolytic viruses are capable of selectively replicating within tumor tissue and can induce a strong immune response. We therefore sought to determine whether these therapies could be rationally combined such that modulation of the tumor microenvironment by the viral therapy could help direct beneficial CTLs induced by the vaccine. As such, we examined the effects of expressing chemokines from oncolytic vaccinia virus, including CCL5 (RANTES), whose receptors are expressed on CTLs induced by different vaccines, including type-1-polarized dendritic cells (DC1). vvCCL5, an oncolytic vaccinia virus expressing CCL5, induced chemotaxis of lymphocyte populations in vitro and in vivo, and displayed improved safety in vivo. Interestingly, enhanced therapeutic benefits with vvCCL5 in vivo correlated with increased persistence of the viral agent exclusively within the tumor. When tumor-bearing mice were both vaccinated with DC1 and treated with vvCCL5 a further significant enhancement in tumor response was achieved which correlated with increased levels of tumor infiltrating lymphocytes. This approach therefore represents a novel means of combining biological therapies for cancer treatment.

1 April 2011 in Journal of Immunotherapy
Verified
Journal Article
Closed access
BHBaocheng Huang
Baocheng Huang
RSRachel Sikorski
Rachel Sikorski
PSPadma Sampath
Padma Sampath
STStephen H. Thorne
Stephen H. Thorne
A variety of immune cell therapies proposed for use in the treatment of cancer, including both autologous cells (Lymphokine Activated Killer, Cytokine Induced Killer) or cell lines (TALL-104, NK-92), rely on recognition of NKG2D ligands on malignant cells for targeting. These ligands, such as MICA and MICB in humans are stress response ligands and are commonly, but not ubiquitously expressed within tumors. Several tumor escape mechanisms have been reported, including ligand downregulation and internalization, or proteolytic cleavage and shedding of their exposed portions (releasing soluble MICA and MICB; sMICA, sMICB). Therefore, an ability to prescreen patients for the level of tumor cell surface expression and shedding of these ligands would prevent needless treatment of patients that are unable to respond, whereas targeted pretreatment of patients to increase surface expression and/or block shedding would enhance the subsequent effectiveness of these therapies. Here, we report that serum tests of sMICA and sMICB in conjunction with tumor measurements might be used to determine rates of shedding from a tumor and that treatment with a selected combination of histone deacetylase inhibitors (to upregulate cell surface MICA/B in some tumors), and metalloproteinase inhibitors (to block MICA/B shedding in others) can be incorporated to regulate cell surface MICA/B levels before immune cell therapy, significantly enhancing their effectiveness (either used alone or as carrier vehicles for oncolytic viruses). Ultimately prescreening patients undergoing such immune cell therapies might be used to personalize cancer treatment regimens based on the NKG2D-ligand status of the tumor.

29 January 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
WHWeizhou Hou
Weizhou Hou
HCHannah Chen
Hannah Chen
JRJuan Jose Rojas
Juan Jose Rojas
PSPadma Sampath
Padma Sampath
STStephen H. Thorne
Stephen H. Thorne
Oncolytic vaccinia virus has been shown to induce a profound, rapid and tumor‐specific vascular collapse in both preclinical models and clinical studies; however, a complete examination of the kinetics and levels of collapse and revascularization has not been described previously. Contrast‐enhanced ultrasound was used to follow tumor perfusion levels in mouse tumor models at times after vaccinia therapy. It was observed that revascularization after viral therapy was dramatically delayed and did not occur until after viral clearance. This indicated that oncolytic vaccinia may possess a previously undescribed antiangiogenic potential that might synergize with the reported anti‐vascular effects. Despite a rapid loss of perfusion and widespread hypoxia within the tumor, it was observed that VEGF levels in the tumor were suppressed throughout the period of active viral infection. Although tumor vasculature could eventually reform after the viral therapy was cleared in mouse models, anti‐tumor effects could be significantly enhanced through additional combination with anti‐VEGF therapies. This was initially examined using a gene therapy approach (Ad‐Flk1‐Fc) to target VEGF directly, demonstrating that the timing of application of the antiangiogenic therapy was critical. However, it is also known that oncolytic vaccinia sensitizes tumors to tyrosine kinase inhibitors (TKI) in the clinic through an unknown mechanism. It is possible this phenomenon may be mediated through the antiangiogenic effects of the TKIs. This was modeled in mouse tumors using sunitinib in combination with oncolytic vaccinia. It was observed that prevention of angiogenesis mediated by oncolytic vaccinia can be utilized to enhance the TKI therapy.

1 December 2012 in Neoplasia
Verified
Journal Article
Open access
PDF file
JLJun Li
Jun Li
MOMark O'MAlley
Mark O'MAlley
PSPadma Sampath
Padma Sampath
PKPawel Kalinski
Pawel Kalinski
DBDavid L. Bartlett
David L. Bartlett
STSteve H. Thorne
Steve H. Thorne
Neoplasia publishes the results of novel investigations in all areas of oncology research.